Vascular Cardiotoxicity of Ponatinib

Status unconfirmed

Conditions studied: Cardiotoxicity

In brief

Pre-clinical studies suggest that the third generation tyrosine kinase inhibitor ponatinib can result in microvascular angiopathy and acceleration of atherosclerosis. This study is intended to examine for myocardial microvascular angiopathy and changes in carotid plaque in patients receiving ponatinib as part of their clinical care.

Key facts

Study ID

NCT03930394

Run by

Oregon Health and Science University

People needed

32

Starts

2019-05-15

Expected to finish

2022-05-01

Last updated by the study team

2019-06-07

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of CML or ALL
• Prescribed ponatinib

You may not qualify if…

• pregnancy or lactation
• major medical illness involving the heart or vasculature (CAD, PAD, DCM).
• hemodynamically unstable
• allergy to ultrasound contrast agents.

Where it is running

• Oregon HSU — Portland, Oregon, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.